EA201992360A1 - Кристаллические формы (s)-афоксоланера - Google Patents

Кристаллические формы (s)-афоксоланера

Info

Publication number
EA201992360A1
EA201992360A1 EA201992360A EA201992360A EA201992360A1 EA 201992360 A1 EA201992360 A1 EA 201992360A1 EA 201992360 A EA201992360 A EA 201992360A EA 201992360 A EA201992360 A EA 201992360A EA 201992360 A1 EA201992360 A1 EA 201992360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline forms
afoxolaner
methods
compositions
preparing
Prior art date
Application number
EA201992360A
Other languages
English (en)
Inventor
Ролоф Йоан Горте Де Ври
Брюно Байон
Сильвен Лафон
Мириам Ге Де Сен Мишель
Стефан Козлович
Original Assignee
БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК. filed Critical БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК.
Publication of EA201992360A1 publication Critical patent/EA201992360A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Secondary Cells (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Настоящее изобретение предлагает кристаллические формы соединения формулы (Ia) и способы получения кристаллических форм. Также предложены композиции, включающие кристаллические формы, и способы использования кристаллических форм.
EA201992360A 2017-04-05 2018-04-05 Кристаллические формы (s)-афоксоланера EA201992360A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482175P 2017-04-05 2017-04-05
PCT/US2018/026328 WO2018187623A1 (en) 2017-04-05 2018-04-05 Crystalline forms of (s)-afoxolaner

Publications (1)

Publication Number Publication Date
EA201992360A1 true EA201992360A1 (ru) 2020-09-02

Family

ID=62092252

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992360A EA201992360A1 (ru) 2017-04-05 2018-04-05 Кристаллические формы (s)-афоксоланера

Country Status (23)

Country Link
US (2) US10662163B2 (ru)
EP (1) EP3606911A1 (ru)
JP (1) JP7222909B2 (ru)
KR (1) KR102612648B1 (ru)
CN (1) CN111032634A (ru)
AR (1) AR111412A1 (ru)
AU (1) AU2018250304B2 (ru)
BR (1) BR112019021072A2 (ru)
CA (1) CA3059114A1 (ru)
CL (1) CL2019002840A1 (ru)
CO (1) CO2019011980A2 (ru)
EA (1) EA201992360A1 (ru)
IL (1) IL269792B (ru)
MD (1) MD20190080A2 (ru)
MX (1) MX2019011931A (ru)
MY (1) MY188420A (ru)
PH (1) PH12019502277A1 (ru)
SG (1) SG11201909229SA (ru)
TW (1) TWI782976B (ru)
UA (1) UA125727C2 (ru)
UY (1) UY37665A (ru)
WO (1) WO2018187623A1 (ru)
ZA (1) ZA201906464B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3059114A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim Animal Health USA Inc. Crystalline forms of (s)-afoxolaner
CN115768753B (zh) * 2020-06-19 2024-04-26 东莞市东阳光动物保健药品有限公司 一种gaba抑制剂的晶型及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
TWI461411B (zh) * 2007-08-17 2014-11-21 Du Pont 製備５－鹵烷基－４，５－二氫異唑衍生物之方法
KR102060464B1 (ko) * 2010-05-27 2019-12-30 이 아이 듀폰 디 네모아 앤드 캄파니 4-[5-[3-클로로-5-(트라이플루오로메틸)페닐]-4,5-다이하이드로-5-(트라이플루오로메틸)-3-아이속사졸릴]-n-[2-옥소-2-[(2,2,2-트라이플루오로에틸)아미노]에틸]-1-나프탈렌카르복스아미드의 결정 형태
TWI567064B (zh) * 2011-09-12 2017-01-21 龍馬躍有限公司 包含異唑啉活性劑之殺寄生蟲組合物、方法及其用途
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
JP2015028006A (ja) * 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法
UY36570A (es) * 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
SG10201912724SA (en) * 2015-04-08 2020-02-27 Boehringer Ingelheim Animal Health Usa Inc Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
BR112018070663A2 (pt) 2016-04-06 2019-02-05 Merial Inc processo para a preparação de compostos de isoxazolina enantiomericamente enriquecidos - solvato de tolueno cristalino de (s)-afoxolaner
CA3059114A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim Animal Health USA Inc. Crystalline forms of (s)-afoxolaner

Also Published As

Publication number Publication date
US20180354917A1 (en) 2018-12-13
IL269792B (en) 2022-04-01
ZA201906464B (en) 2021-08-25
BR112019021072A2 (pt) 2020-05-12
UA125727C2 (uk) 2022-05-25
CA3059114A1 (en) 2018-10-11
KR102612648B1 (ko) 2023-12-11
JP2020513010A (ja) 2020-04-30
CN111032634A (zh) 2020-04-17
IL269792A (en) 2019-11-28
SG11201909229SA (en) 2019-11-28
AU2018250304B2 (en) 2022-03-03
KR20190136055A (ko) 2019-12-09
AU2018250304A1 (en) 2019-10-31
MX2019011931A (es) 2020-01-13
PH12019502277A1 (en) 2020-09-14
CO2019011980A2 (es) 2020-02-18
UY37665A (es) 2018-10-31
MY188420A (en) 2021-12-08
AR111412A1 (es) 2019-07-10
TWI782976B (zh) 2022-11-11
US10662163B2 (en) 2020-05-26
US20200270219A1 (en) 2020-08-27
CL2019002840A1 (es) 2020-01-10
TW201841895A (zh) 2018-12-01
JP7222909B2 (ja) 2023-02-15
US11130739B2 (en) 2021-09-28
WO2018187623A1 (en) 2018-10-11
MD20190080A2 (ru) 2020-04-30
EP3606911A1 (en) 2020-02-12
WO2018187623A8 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
PH12018500457A1 (en) New phenoxymethyl derivatives
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201892147A1 (ru) Бициклические соединения
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
EA201691799A1 (ru) Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
EA201791304A1 (ru) Производные изохинолина для лечения вич
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2016011992A (es) Derivados de piperidina-diona.
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201792021A1 (ru) Ингибитор jak
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
EA201790570A1 (ru) Модуляторы р2х7
EA201790400A1 (ru) Зонды для визуализации белка хантингтина